WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

A ALIMENTARY TRACT AND METABOLISM
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A07E INTESTINAL ANTIINFLAMMATORY AGENTS

A07EA Corticosteroids acting locally

Enemas and rectal foams for treatment of e.g. ulcerative colitis are classified here. Oral corticosteroids solely indicated for the treatment of intestinal inflammatory diseases are also classified here.
Sublingual formulations of budesonide for the treatment of eosinophilic esophagitis and oral formulations of budesonide for the treatment of primary immunoglobulin A nephropathy are classified in this group.

The DDDs are given as 1 enema. The DDD for hydrocortisone rectal foam is given in amount of active substance.
The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.

A07EB Antiallergic agents, excl. corticosteroids

Cromoglicic acid for oral use in food allergy is classified in this group.

The DDD is based on treatment of food allergy.

A07EC Aminosalicylic acid and similar agents

Some preparations classified in this group are also used for treatment of rheumatoid arthritis.

The DDDs are based on treatment of colitis ulcerosa and morbus Crohn.

Last updated: 2024-01-26